Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol in Niemann-Pick Disease Type C
NCT02612129Phase 3Completed
- Sponsor
- Zevra Therapeutics
- Start
- Jun 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of arimoclomol in Niemann-Pick disease type C (NPC), sponsored by Zevra Therapeutics. Started Jun 2016; status: completed.
02
Drugs
arimoclomol
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NCT02612129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612129.